27.50USD-0.54%Mkt Cap: 382.18M USDP/E: —Last update: 2026-05-26
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product c…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap382.18M USD
Enterprise Value372.90M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-15.79M USD
Revenue/Share—
Last Price27.50 USD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-33.16
PEG—
EV/EBITDA-19.04
EV/Revenue—
P/S—
P/B172.09
EPS (TTM)-1.46
EPS (Forward)-0.82
52W Range
7.78075% of range34.10
52W High34.10 USD
52W Low7.780 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-623.07%
ROA-385.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.27M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-0.36%
Net Debt-3.81M USD
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity—
Current Ratio2.35
Quick Ratio2.35
Book Value/Sh0.1580 USD
Cash/Share0.2750 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)47.50 USD
Target Range45.00 USD – 50.00 USD
# Analysts2
Ownership
Shares Out.13.85M
Float6.57M
Insiders50.71%
Institutions13.15%
Short Interest
Short Ratio11.6d
Short % Float22.50%
Short % Out.11.15%
Shares Short1.54M
Short (prev mo.)1.50M
Technical
SMA 5024.87 (+10.6%)
SMA 20017.99 (+52.9%)
Beta1.39
S&P 52W Chg28.31%
Avg Vol (30d)127.72K
Avg Vol (10d)135.72K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—